You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
孔繁毅:值得引入復必泰雙價疫苗
阿思達克 10-10 10:06
政府接獲復必泰針對Omicron BA.4和BA.5研發的雙價疫苗認可申請。政府專家顧問、疫苗顧問專家委員會成員孔繁毅在電台節目表示,尚未收到相關章程,相信衛生署處理完相關資料後,會交予新冠疫苗顧問專家委員會審視。他認為雙價疫苗值得引入,雖然針對的病毒株未必吻合,但效用仍好過初代疫苗。 孔繁毅表示,現時正在海外傳播的新變異病毒株BA.2.75.2,對於供有免疫系統問題病人注射、用作防感染的抗體藥劑製品「Evusheld」,有強烈抗藥性,惟目前仍能以抗病毒口服藥治療。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account